Pancreatic duct stenting decreases the incidence of post-ERCP pancreatitis: A prospective randomized study

Meyerson, S. M.; Geenen, JE; Johnson, G. K.; Catalano, MF; Geenen, D. J.; Schmalz, Michael J.; Hogan, W. J.

doi:10.1016/s0016-5085(98)81956-2

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The widely accepted mechanism of pathogenesis is that the relative constriction of the minor papilla in patients with pancreas divisum is believed to impede the passage of pancreatic secretions, hence increasing intraductal pressure and leading to pancreatitis. The cessation of pancreatitis attacks after minor papilla sphincterotomy or stent placement to the minor papilla supports this view [9][10][11]16].…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

The effects of contrast agent and intraductal pressure changes on the development of pancreatitis in an ERCP model in rats

Haciahmetoglu

Ertekın

Dolay

et al. 2007

Langenbecks Arch Surg

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 93%

“…However, only a few studies have evaluated the techniques and contrast drugs used during ERCP; therefore, the effects of these factors are still controversial [9][10][11].…”

Section: Introductionmentioning

confidence: 99%

The effects of contrast agent and intraductal pressure changes on the development of pancreatitis in an ERCP model in rats

Haciahmetoglu

Ertekın

Dolay

et al. 2007

Langenbecks Arch Surg

View full text Add to dashboard Cite

show abstract

“…Furthermore, it requires another endoscopy to remove the stent placed, increasing therefore the chance of tissue damage. In prospective studies, the failure rate of pancreatic stenting is normally around 5-10% [2][3][4][5]. Freeman [20] has proposed to weigh up the pros and cons carefully before applying pancreatic stenting.…”

Section: Discussionmentioning

confidence: 99%

“…Randomized prospective studies have reported overall pancreatitis rates of 2-7% after ERCP, and of 30-50% in high-risk patients [2][3][4][5]. A study by Andriulli et al [6] summarized 16,855 cases who underwent ERCP from 1977 to 2006, and found 585 patients who developed PEP (3.5%).…”

Section: Introductionmentioning

confidence: 99%

Clinical Study on the Prevention of Post-ERCP Pancreatitis by Pancreatic Duct Stenting

Pan

Dang

Meng

et al. 2011

Cell Biochem Biophys

View full text Add to dashboard Cite

Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is one of the most common and serious complications of ERCP, which has become a major concern for digestive endoscopists. In the present study, we examine whether pancreatic duct stenting can reduce the incidence of PEP. Forty patients who underwent an ERCP in our hospital were selected according to their risk factors for PEP. They were randomly divided into two groups: (1) 20 subjects received a pancreatic duct stenting after ERCP to prevent pancreatitis (stent group, S); and (2) the other 20 subjects did not receive pancreatic duct stenting after ERCP (non-stent group, NS). Urine and serum amylase, and serum lipase were determined after the operation; symptoms of abdominal pain were monitored; cost of hospitalization was evaluated for the comparison. The results show that (1) 18 cases developed PEP, and they were significantly less in S group than in NS group (4 vs. 14 cases; P < 0.01); (2) Serum amylase was significantly lower in S group than in NS group (197.8 ± 339.7 vs. 825.4 ± 1253.4 U/l, respectively; P < 0.05); (3) The intensity of abdominal pain was 3.4 ± 0.8 in S group, compared to 4.1 ± 1.2 in NS group; (4) Duration of pharmaceutical treatment was not significantly different between the two groups (4.2 ± 1.4 vs. 6.1 ± 2.3 days, in S and NS group, respectively); and (5) The total hospitalization cost was significantly less in S group (8928 ± 2635 RMB) than in NS group (11288 ± 4325 RMB; P < 0.05). It is concluded that pancreatic duct stenting can reduce the incidence of PEP, shorten the duration of hospitalization, and therefore, lessen patients' financial burden. It is shown to be an effective way to prevent PEP.

show abstract

Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials

Singh¹,

Das²,

Isenberg³

et al. 2004

Gastrointestinal Endoscopy

311

182

View full text Add to dashboard Cite

Pancreatic duct stenting decreases the incidence of post-ERCP pancreatitis: A prospective randomized study

Cited by 3 publications

References 0 publications

The effects of contrast agent and intraductal pressure changes on the development of pancreatitis in an ERCP model in rats

The effects of contrast agent and intraductal pressure changes on the development of pancreatitis in an ERCP model in rats

Clinical Study on the Prevention of Post-ERCP Pancreatitis by Pancreatic Duct Stenting

Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials

Contact Info

Product

Resources

About